HEALTHglobal
J&J wins FDA nod for psoriasis pill that aims to compete with top-selling injections
Single source
Updated 2 hours ago
First seen March 18, 2026 17:11:22Stay on top of this story
Follow the names and topics behind it.
Add this story's key topics to your watchlist so LyscoNews can highlight related developments and future matches.
Create a free account to sync your watchlist, saved stories, and alerts across devices.
Quick Summary
The clearance is the first for an oral peptide that blocks IL-23, the target of popular medicines like Skyrizi and Tremfya. J&J has said the new drug, Icotyde, has the potential to top $5 billion in sales.